Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Russell

Showing results (841-850 of 851) with videos related to

Pageof 86
Sort By:
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Mucosal Immunology|November 2, 2017
NOX1 loss-of-function genetic variants in patients with inflammatory bowel diseaseT Schwerd, R V Bryant, S Pandey, et al.
Nature Communications|February 22, 2020
Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel diseaseEva Gonçalves Serra, Tobias Schwerd, Loukas Moutsianas, et al.
JAMA|February 27, 2019
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel DiseaseGareth J Walker, James W Harrison, Graham A Heap, et al.
Nature Genetics|September 15, 2014
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressantsGraham A Heap, Michael N Weedon, Claire M Bewshea, et al.
Nature Communications|October 10, 2015
Genetic sharing and heritability of paediatric age of onset autoimmune diseasesYun R Li, Sihai D Zhao, Jin Li, et al.
Nature Medicine|August 25, 2015
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseasesYun R Li, Jin Li, Sihai D Zhao, et al.
Scientific Data|November 11, 2023
Global dataset of soil organic carbon in tidal marshesTania L Maxwell, André S Rovai, Maria Fernanda Adame, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Nature|November 7, 2012
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseLuke Jostins, Stephan Ripke, Rinse K Weersma, et al.
Pageof 86

Showing results (841-850 of 851) with videos related to

Sort By:
Pageof 86
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Mucosal Immunology|November 2, 2017
NOX1 loss-of-function genetic variants in patients with inflammatory bowel diseaseT Schwerd, R V Bryant, S Pandey, et al.
Nature Communications|February 22, 2020
Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel diseaseEva Gonçalves Serra, Tobias Schwerd, Loukas Moutsianas, et al.
JAMA|February 27, 2019
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel DiseaseGareth J Walker, James W Harrison, Graham A Heap, et al.
Nature Genetics|September 15, 2014
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressantsGraham A Heap, Michael N Weedon, Claire M Bewshea, et al.
Nature Communications|October 10, 2015
Genetic sharing and heritability of paediatric age of onset autoimmune diseasesYun R Li, Sihai D Zhao, Jin Li, et al.
Nature Medicine|August 25, 2015
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseasesYun R Li, Jin Li, Sihai D Zhao, et al.
Scientific Data|November 11, 2023
Global dataset of soil organic carbon in tidal marshesTania L Maxwell, André S Rovai, Maria Fernanda Adame, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Nature|November 7, 2012
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseLuke Jostins, Stephan Ripke, Rinse K Weersma, et al.
Pageof 86